Phase III
Ferring Pharmaceuticals is buying Rebiotix. As part of the deal, will acquire Rebiotix’s lead program, RBX2660, a non-antibiotic treatment to prevent recurring Clostridium difficile infection (CDI).
On Target Laboratories announced that the first patient was treated in its Phase III trial of OTL38 in detecting ovarian cancer. Linked with a near-infrared dye, OTL38 allows surgeons to visually identify cancer cells that can guide them in removing the cancer tissue.
Boehringer Ingelheim and OSE Immunotherapeutics signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.
Allergan and its developmental partner Gedeon Richter Ltd. are eying an add-on approval from the U.S. Food and Drug Administration for a depression treatment based on new Phase III data released Tuesday.
Eli Lilly and Company announced top-line data from its Phase III REACH-2 trial of Cyramza (ramucirumab) as a monotherapy second-line treatment for hepatocellular carcinoma (HCC), which is liver cancer.
Pfizer could be eying the green light for a first-ever regulatory approved treatment for transthyretin cardiomyopathy (TTR) following positive topline results from a late-stage study.
Heron Therapeutics is looking to raise money to fund a potential launch of its anesthetic for bunionectomy and hernia repair by selling six million shares of its common stock.
Shares of Edge Therapeutics were in free fall Wednesday afternoon following the company’s decision to discontinue development of a late stage treatment for adults with aneurysmal subarachnoid hemorrhage (aSAH).
Analysts look at what else AbbVie has in the pipeline after Rova-T Failure.
Biohaven Pharmaceutical released positive top-line results from two Phase III clinical trials of rimegepant for migraine. Despite the positive data, shares were down more than 30 percent in early trading this morning.
PRESS RELEASES